Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Matthew Langer Meyerson, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Matthew Meyerson and Gad Getz.
Connection Strength

5.794
  1. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012 Sep 27; 489(7417):519-25.
    View in: PubMed
    Score: 0.531
  2. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet. 2010 Oct; 11(10):685-96.
    View in: PubMed
    Score: 0.464
  3. Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing. Cell. 2018 07 12; 174(2):433-447.e19.
    View in: PubMed
    Score: 0.198
  4. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun. 2017 11 06; 8(1):1324.
    View in: PubMed
    Score: 0.190
  5. Recurrent and functional regulatory mutations in breast cancer. Nature. 2017 07 06; 547(7661):55-60.
    View in: PubMed
    Score: 0.185
  6. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet. 2016 06; 48(6):607-16.
    View in: PubMed
    Score: 0.171
  7. Oncotator: cancer variant annotation tool. Hum Mutat. 2015 Apr; 36(4):E2423-9.
    View in: PubMed
    Score: 0.158
  8. Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab. Mol Cancer. 2014 Jun 04; 13:141.
    View in: PubMed
    Score: 0.150
  9. Somatic retrotransposition in human cancer revealed by whole-genome and exome sequencing. Genome Res. 2014 Jul; 24(7):1053-63.
    View in: PubMed
    Score: 0.149
  10. A pan-cancer analysis of transcriptome changes associated with somatic mutations in U2AF1 reveals commonly altered splicing events. PLoS One. 2014; 9(1):e87361.
    View in: PubMed
    Score: 0.146
  11. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014 Jan 23; 505(7484):495-501.
    View in: PubMed
    Score: 0.146
  12. Landscape of genomic alterations in cervical carcinomas. Nature. 2014 Feb 20; 506(7488):371-5.
    View in: PubMed
    Score: 0.145
  13. Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat Genet. 2013 Dec; 45(12):1483-6.
    View in: PubMed
    Score: 0.144
  14. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013 Jul 11; 499(7457):214-218.
    View in: PubMed
    Score: 0.140
  15. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013 Mar; 31(3):213-9.
    View in: PubMed
    Score: 0.137
  16. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012 Sep 14; 150(6):1107-20.
    View in: PubMed
    Score: 0.133
  17. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A. 2012 Sep 04; 109(36):14476-81.
    View in: PubMed
    Score: 0.132
  18. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 2012 Jun 20; 486(7403):405-9.
    View in: PubMed
    Score: 0.131
  19. Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol. 2012 May; 30(5):413-21.
    View in: PubMed
    Score: 0.130
  20. Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat Genet. 2011 Sep 04; 43(10):964-968.
    View in: PubMed
    Score: 0.124
  21. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011; 12(4):R41.
    View in: PubMed
    Score: 0.121
  22. Making sense of cancer genomic data. Genes Dev. 2011 Mar 15; 25(6):534-55.
    View in: PubMed
    Score: 0.120
  23. The landscape of somatic copy-number alteration across human cancers. Nature. 2010 Feb 18; 463(7283):899-905.
    View in: PubMed
    Score: 0.111
  24. Characterizing the cancer genome in lung adenocarcinoma. Nature. 2007 Dec 06; 450(7171):893-8.
    View in: PubMed
    Score: 0.095
  25. Comment on "The consensus coding sequences of human breast and colorectal cancers". Science. 2007 Sep 14; 317(5844):1500.
    View in: PubMed
    Score: 0.094
  26. Integrated genomic characterization of endometrial carcinoma. Nature. 2013 May 02; 497(7447):67-73.
    View in: PubMed
    Score: 0.069
  27. Whole-genome characterization of lung adenocarcinomas lacking the RTK/RAS/RAF pathway. Cell Rep. 2021 02 02; 34(5):108707.
    View in: PubMed
    Score: 0.059
  28. Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. Clin Cancer Res. 2020 06 01; 26(11):2556-2564.
    View in: PubMed
    Score: 0.056
  29. Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2019 01; 565(7738):E5-E6.
    View in: PubMed
    Score: 0.051
  30. Tumor fraction in cell-free DNA as a biomarker in prostate cancer. JCI Insight. 2018 11 02; 3(21).
    View in: PubMed
    Score: 0.051
  31. Mutational processes shape the landscape of TP53 mutations in human cancer. Nat Genet. 2018 10; 50(10):1381-1387.
    View in: PubMed
    Score: 0.050
  32. Genetic and transcriptional evolution alters cancer cell line drug response. Nature. 2018 08; 560(7718):325-330.
    View in: PubMed
    Score: 0.050
  33. Publisher Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018 Aug; 24(8):1292.
    View in: PubMed
    Score: 0.050
  34. Author Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018 Aug; 24(8):1290-1291.
    View in: PubMed
    Score: 0.050
  35. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018 05; 24(5):679-690.
    View in: PubMed
    Score: 0.049
  36. SvABA: genome-wide detection of structural variants and indels by local assembly. Genome Res. 2018 04; 28(4):581-591.
    View in: PubMed
    Score: 0.049
  37. Whole Exome Sequencing Identifies TSC1/TSC2 Biallelic Loss as the Primary and Sufficient Driver Event for Renal Angiomyolipoma Development. PLoS Genet. 2016 08; 12(8):e1006242.
    View in: PubMed
    Score: 0.044
  38. High-throughput Phenotyping of Lung Cancer Somatic Mutations. Cancer Cell. 2016 08 08; 30(2):214-228.
    View in: PubMed
    Score: 0.043
  39. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015 Nov; 5(11):1164-1177.
    View in: PubMed
    Score: 0.041
  40. Exome sequencing of pleuropulmonary blastoma reveals frequent biallelic loss of TP53 and two hits in DICER1 resulting in retention of 5p-derived miRNA hairpin loop sequences. Oncogene. 2014 Nov 06; 33(45):5295-302.
    View in: PubMed
    Score: 0.037
  41. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol. 2014 May; 32(5):479-84.
    View in: PubMed
    Score: 0.037
  42. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov. 2014 Feb; 4(2):216-31.
    View in: PubMed
    Score: 0.037
  43. Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients. J Clin Oncol. 2014 Jan 10; 32(2):121-8.
    View in: PubMed
    Score: 0.036
  44. Pan-cancer patterns of somatic copy number alteration. Nat Genet. 2013 Oct; 45(10):1134-40.
    View in: PubMed
    Score: 0.036
  45. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res. 2013 Aug 15; 73(16):5195-205.
    View in: PubMed
    Score: 0.035
  46. Punctuated evolution of prostate cancer genomes. Cell. 2013 Apr 25; 153(3):666-77.
    View in: PubMed
    Score: 0.035
  47. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013 Feb 14; 152(4):714-26.
    View in: PubMed
    Score: 0.034
  48. The genetic landscape of high-risk neuroblastoma. Nat Genet. 2013 Mar; 45(3):279-84.
    View in: PubMed
    Score: 0.034
  49. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature. 2012 Aug 02; 488(7409):106-10.
    View in: PubMed
    Score: 0.033
  50. A landscape of driver mutations in melanoma. Cell. 2012 Jul 20; 150(2):251-63.
    View in: PubMed
    Score: 0.033
  51. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature. 2012 May 09; 485(7399):502-6.
    View in: PubMed
    Score: 0.032
  52. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012 Mar 28; 483(7391):603-7.
    View in: PubMed
    Score: 0.032
  53. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011 Dec 29; 365(26):2497-506.
    View in: PubMed
    Score: 0.032
  54. High order chromatin architecture shapes the landscape of chromosomal alterations in cancer. Nat Biotechnol. 2011 Nov 20; 29(12):1109-13.
    View in: PubMed
    Score: 0.031
  55. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011 Aug 26; 333(6046):1157-60.
    View in: PubMed
    Score: 0.031
  56. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci U S A. 2011 Jul 26; 108(30):12372-7.
    View in: PubMed
    Score: 0.031
  57. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011 Mar 24; 471(7339):467-72.
    View in: PubMed
    Score: 0.030
  58. The genomic complexity of primary human prostate cancer. Nature. 2011 Feb 10; 470(7333):214-20.
    View in: PubMed
    Score: 0.030
  59. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet. 2010 Aug; 42(8):715-21.
    View in: PubMed
    Score: 0.029
  60. Integrative analysis of the melanoma transcriptome. Genome Res. 2010 Apr; 20(4):413-27.
    View in: PubMed
    Score: 0.028
  61. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010 Jan 19; 17(1):98-110.
    View in: PubMed
    Score: 0.028
  62. High-resolution mapping of copy-number alterations with massively parallel sequencing. Nat Methods. 2009 Jan; 6(1):99-103.
    View in: PubMed
    Score: 0.026
  63. Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res. 2008 Feb 01; 68(3):664-73.
    View in: PubMed
    Score: 0.024
  64. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A. 2007 Dec 11; 104(50):20007-12.
    View in: PubMed
    Score: 0.024
  65. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med. 2006 Dec; 3(12):e485.
    View in: PubMed
    Score: 0.022
  66. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature. 2005 Jul 07; 436(7047):117-22.
    View in: PubMed
    Score: 0.020
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.